We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Tufts: FDA, EU Likely to Up Use Of Special Designations in 2013
Tufts: FDA, EU Likely to Up Use Of Special Designations in 2013
January 16, 2013
U.S. and EU regulators hope to increase the use of special designations — such as fast track, priority review and accelerated approval — to speed approvals of drugs for rare and/or life-threatening noncancer diseases, according to a Tufts University report.